Argyll Diagnostics

Argyll Diagnostics endeavors to understand the true essence behind the [business and economic] decisions people make every day. To do this we interviewed thousands of healthcare clinicians and formed limited ventures with various biotech firms to study and field test human diagnostic protocols from the physical, emotional & mental perspectives. These included… genetic testing clinical trial for individual propensities for physical addiction to opioids and pain perception (Proove Biosciences); emotional/stress levels connected to physical certain symptoms (AssessMD); key areas of interest & reactive behaviors based upon unmet expectations (Birkman International); the origins of Behavioral Economics (Kahneman, Tversky & Thaler, et al.); we even studied the adolescent mental health factors connected to bullying in US schools (AssessFast). In early 2017, Argyll Diagnostics developed an algorithm to effectively assess susceptibility to Cognitive Blind spots. Argyll Diagnostics is a privately held healthcare think tank of Argyll & Co.